** Drugmaker BioMarin Pharmaceutical's BMRN.O shares rise ~1.8% to $68.25 premarket
** Oppenheimer upgrades BMRN to "outperform" from "perform" rating
** Brokerage says new management's focus on operational efficiencies, cost reduction and return on R&D investments will boost BMRN's revenue growth
** Twenty-three of 29 brokerages rate the stock "buy" or higher, 6 "hold"; their median PT is $95 - data compiled by LSEG
** As of last close, stock up ~3.8% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。